Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13920413 | 0.81 | NPC1 (0.47) | MAPTMEN1KMT2AALDH1A1PDPK1 | |
| SCHEMBL17895492 | 0.81 | GAA (0.40) | — | |
| SCHEMBL6102242 | 0.76 | MAPT (0.35) | MAPTMEN1KMT2AALDH1A1PDPK1 | |
| SCHEMBL13920414 | 0.76 | MAPT (0.32) | MAPTMEN1KMT2AALDH1A1PDPK1 | |
| SCHEMBL17453457 | 0.75 | MRGPRX1 (0.41) | MAPTMEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL15472012 | 0.74 | RXFP1 (0.39) | MAPTALDH1A1NPC1RAB9APKM | |
| SCHEMBL9920604 | 0.73 | MAPT (0.33) | MAPTALDH1A1PIK3CD | |
| SCHEMBL5663577 | 0.73 | CDC7 (0.32) | MAPTALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL31261844 | 0.73 | MAPT (0.33) | MAPTALDH1A1 | |
| SCHEMBL22651286 | 0.73 | ALDH1A1 (0.38) | MAPTMEN1KMT2AALDH1A1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739671-A1 | NEW COMPOUNDS | Aston University (GB) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025008627-A1 | NEW COMPOUNDS | ASTON UNIVERSITY (GB) | 2025-01-09 | — | — | WO | disclosed |
| US-20210292337-A1 | THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2021-09-23 | — | — | US | disclosed |
| US-10906916-B2 | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10377767-B2 | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180346480-A1 | THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2018-12-06 | — | — | US | disclosed |
| US-9932351-B2 | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932351-B2 | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20160229864-A1 | THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160229864-A1 | THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2016-08-11 | — | — | US | disclosed |
| EP-2616471-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012037141-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037141-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120065200-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2012-03-15 | — | — | US | disclosed |
| US-20120065200-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2012-03-15 | — | — | US | disclosed |
| US-20120065200-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2012-03-15 | — | — | US | disclosed |
| EP-1773843-A4 | SMALL MOLECULE THIENOPYRIMIDINE-BASED PROTEIN TYROSINE KINASE INHIBITORS | UNIV TEXAS (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1773843-A1 | SMALL MOLECULE THIENOPYRIMIDINE-BASED PROTEIN TYROSINE KINASE INHIBITORS | The Board of Regents of The University of Texas System (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014404-A1 | SMALL MOLECULE THIENOPYRIMIDINE-BASED PROTEIN TYROSINE KINASE INHIBITORS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060004002-A1 | Small molecule thienopyrimidine-based protein tyrosine kinase inhibitors | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229864-A1 | THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, USP1 | MAPT 1393/4885MEN1 2150/4885KMT2A 2473/4885 |
| US-20060004002-A1 | Small molecule thienopyrimidine-based protein tyrosine kinase inhibitors | SRC, LCK, FYN | MAPT 868/4885MEN1 2150/4885KMT2A 682/4885 |
| US-20210292337-A1 | THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, USP1 | MAPT 1393/4885MEN1 2150/4885KMT2A 2473/4885 |
| US-20180346480-A1 | THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, USP1 | MAPT 1393/4885MEN1 2150/4885KMT2A 2473/4885 |
| US-20120065200-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | NOTUM, GLA, CES1 | MAPT 4363/4885MEN1 2728/4885KMT2A 527/4885 |
| US-10377767-B2 | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, USP1 | MAPT 1393/4885MEN1 2150/4885KMT2A 2473/4885 |
| US-10906916-B2 | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, USP1 | MAPT 1393/4885MEN1 2150/4885KMT2A 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.